

Pharmacovigilance Focus

Monitoring the safety of off-label medicine use

Medicine labels contain important information on the conditions of use. These conditions typically include the indication, dosage, frequency of administration, and route of administration. Other important conditions of use can include the age range of patients, duration of treatment, and contraindications to use of the medicine. Deviations from the conditions of use set forth in the label constitute off-label use.

In the USA, off-label use is legal. While the Food and Drug Administration (FDA) regulates the marketing of medicines, it does not regulate prescribing practices. In one study (1), approximately 21 per cent of drug use in office-based practice was for off-label use. Off-label use may occur for a variety of reasons. For example, there are some diseases for which no adequate, labelled treatment exists. In these situations, prescribers use medicines for off-label indications. In the case of medicines for children, many drugs have never been studied in children, so there has been extensive off-label use in children, although there are ongoing efforts to correct this situation. In some cases, there may be a reasonable body of published evidence to support off-label use. In other cases, such use is speculative. However, off-label use may become part of accepted practice, and may be part of professional society guidelines.

Because off-label use is common, there is a public health imperative to monitor the

safety of medicines when used off-label. First and foremost, monitoring the safety of medicines in off-label settings is necessary to gain information on the usage of medicines in these settings. While formal study of medication safety would be optimal in these settings, such studies are often not available. Thus, safety monitoring plays a critical role. Data derived from monitoring safety in an off-label setting can also potentially be relevant to the safety of the medicine when used according to the label. In addition, data derived in the off-label setting may serve as a stimulus for more formal study.

There are many specific concerns that need to be addressed when monitoring the safety of medicines in an off-label setting. Many factors that could affect the safety of the medicine could be different in the off-label compared to the on-label setting. These factors include the age of patients, range of co-morbidities, use of concomitant medication, drug-disease interactions and differences in pharmacokinetics and pharmacodynamics.

Despite the importance of monitoring the safety of medicines in an off-label setting, there are many challenges that this situation presents. First, spontaneous reports do not always contain the indication for use or other details that would allow one to determine that the medicine was used in a manner not consistent with the product's label. Second, the identification of an adverse drug reaction in the off-label setting does not necessarily mean that this reaction is limited to that setting.

Article prepared by Gerald J. Dal Pan, MD, MHS, Food and Drug Administration, USA. (Views expressed are those of the author, and not necessarily those of the US Food and Drug Administration.)

Despite these limitations, spontaneous reports can be useful in determining adverse drug reactions when medicines are used off-label.

Drug utilization databases may be helpful in monitoring off-label use of medicines. Though such databases do not typically contain information on indications for use, they can be helpful in identifying other aspects of off-label use. For example, drug utilization data may shed light on the age range of patients using a medicine, the duration of therapy, concomitant medication used, and dosages prescribed. Review of such data may indicate that there is substantial off-label use and this may provide valuable information for safety monitoring purposes.

Drug use databases typically do not have any information on medical diagnoses, so they are not suitable for identifying adverse events. Nonetheless, they can be useful for identifying trends that may require further study. Administrative healthcare databases that contain information both on drug use data and medical diagnoses can also be useful for identifying trends in off-label use, though medical record review may be necessary to determine the indication for usage. Electronic medical records may be more useful than administrative healthcare databases if indication for use is linked to the drug prescribed. Finally, published clinical trials studying off-label use may be a valuable source of information on adverse drug reactions. However, the limitations of clinical trials for ascertaining adverse event information are well known.

One example of the importance of monitoring for adverse events in the off-label setting is seen with the drug tiagabine, whose labelled indication in the USA is for adjunctive therapy in adults and children over 12 years of age in the treatment of partial seizures. Post-marketing reports indicated that this medicine was being

used by persons without epilepsy, and that these persons experienced seizures after tiagabine was started. The product's label was updated to include this information.

In summary, the off-label use of medicines is common. Monitoring of adverse events in this setting is important, though there are many challenges in doing so.

Reference: Radley et al. *Arch Intern Med* 2006; **166**:1021-1026.

Drotrecogin alfa: what relation to thrombosis?

Drotrecogin alfa (activated) is a recombinant form of human activated protein C that has antithrombotic, anti-inflammatory and profibrinolytic activities. It is used mainly in intensive care as a treatment for severe sepsis (sepsis associated with acute organ dysfunction). It is administered in multiple slow infusions, as a rule, at a dose of 24 µg/kg/hour for four days (1).

Sepsis is a complex illness involving both infection and inflammation when the body's response is systemic, instead of being localized to the site of infection. This "overreaction" to the infection may result in organ damage and is more dangerous than the initial infection itself (2).

Patients who die during episodes of sepsis are more likely to have coagulation defects, including lower levels of circulating antithrombin III and protein C. The latter is a vitamin K-dependent anticoagulant protease. In sepsis, protein C deficiency appears before the onset of observable indicators of septic shock.

The administration of an exogenous analogue may modulate the patient's

*Article prepared by Tamás Paál, Hungary.
(Signal Reviewer for the WHO Programme for International Drug Monitoring.)*

response during sepsis (1, 3). The only serious adverse reaction observed in clinical trials to drotrecogin alfa was bleeding (3, 4).

Description of new ADR reports

Thirteen non-duplicate reports of thrombotic events in septic patients treated with drotrecogin alfa were reported to VigiBase, the database of the WHO Collaborating Centre for International Drug Monitoring, in the period 2002 to 2007. There were 12 reports from the USA and one from the United Kingdom. The reports are summarized below.

1. A General Practitioner (GP) described a 66-year-old male who developed thrombosis after administration of drotrecogin alfa. No details were reported.

2. A 72-year-old male was treated with drotrecogin alfa for three days. On the second day of treatment, pulmonary haemorrhage and thrombosis were observed.

3. A 34-year-old male was treated with drotrecogin alfa for six days in 2002. Concomitant medication comprised antibiotics as well as paracetamol and hydrocodone bitartrate. The report, sent by a GP, specified thrombosis, multiple organ failure and gangrene as adverse effects. Onset appeared eight days after termination of treatment.

4. A 66-year-old male was treated with drotrecogin alfa for three days. Concomitant medication comprised paracetamol, codeine, atenolol, lorazepam, triamcinolone, propofol, dopamine, levofloxacin, morphine, famotidine, salbutamol, metoclopramide, diazepam, midazolam, thiamine, piperacillin-tazobactam combination and heparin. The dosage and other treatment data were missing. Adverse reactions observed on the last

day of drotrecogin treatment were deep venous thrombophlebitis and thrombosis.

5. A pharmacist described a 45-year-old female who was administered drotrecogin alfa for four days. Concomitant medication comprised dopamine and norepinephrine. Adverse effects described were intestinal ischaemia, decreased prothrombin level and thrombosis.

6. A pharmacist described a 72-year-old male treated with drotrecogin alfa for four days. Concomitant medication comprised sodium bicarbonate, pantoprazole, norepinephrine, vasopressin, paracetamol, dopamine, amiodarone, vancomycin and piperacillin-tazobactam combination. Adverse reactions described were anaemia, discoloured faeces and thrombosis.

7. A 68-year-old male was administered drotrecogin alfa for five days. Concomitant medication comprised cefotaxime, clarithromycin, amiodarone for two days, hydrocortisone for eight days and lorazepam for two days. One day after termination of drotrecogin treatment the patient developed thrombosis.

8. A pharmacist described an 86-year-old male who was treated with drotrecogin alfa for two days. No concomitant medication was reported. Life-threatening adverse reactions comprised hypotension, gastrointestinal haemorrhage and thrombosis. Positive dechallenge was also observed.

9. A physician reported the case of a female treated with drotrecogin alfa who developed thrombosis. No details were disclosed.

10. A pharmacist described a 63-year-old female treated with drotrecogin alfa for three days. Concomitant medication comprised ranitidine, azithromycin, ceftriaxone, dopamine and norepinephrine. Adverse reactions reported were

increased blood chloride and urea, hypernatraemia, hypokalaemia, hyperglycaemia, peripheral oedema, thrombocythaemia and thrombosis. Dechallenge appeared to be negative. No further information was provided.

11. A physician described a 70-year-old female treated with drotrecogin alfa for two days. Reported adverse effects were rash, jaundice, rectal disorders, bacterial infection, peritonitis and thrombosis.

12. A health professional reported the case of a 29-year-old female treated with drotrecogin alfa for two days. Concomitant medication comprised norepinephrine and dobutamine. Adverse reactions were haemorrhage and thrombosis.

13. A physician reported a 30-year-old female who was administered drotrecogin alfa (no other information was available). The adverse reaction was thrombosis.

Evaluation of reports

Six of the thirteen reports do not mention concomitant medication. Because of the clinical situation in which drotrecogin is used, it is almost certain that other medicines were co-administered. Thus, it is possible that some concomitantly used but undisclosed medicine might have contributed to the adverse effect.

Seven reports (3, 4, 5, 6, 7, 10 and 12) describe a range of concomitant medications. According to European Union Summaries of Product Characteristics (SPCs) as well as an international database (5) of these medicines, only propofol (administered in a single case) has the recognized, although very rare, adverse effect of thrombophlebitis (6).

Signal assessment

On the basis of pharmacological properties of drotrecogin alfa, administration is unlikely to lead to thrombosis. On the contrary, drotrecogin use is frequently

associated with bleeding, related to its antithrombotic and profibrinolytic properties (1). In a Phase III placebo controlled clinical trial, the incidence of thrombotic events was similar in the drotrecogin and placebo arms (4). This was confirmed by analysis of results from combined clinical trials. When compared with placebo, patients in the active treatment arms experienced numerically fewer thrombotic events, although the difference was not statistically significant (7).

Thrombosis frequently occurs in patients with severe sepsis (7). Disseminated intravascular coagulation (DIC) may develop in 30-50% of patients with severe sepsis and septic shock, especially when caused by Gram negative bacteria. The mortality of sepsis is correlated with the development and severity of DIC (8). Protein C serves as an important anticoagulant compensatory mechanism. The cytokines produced in sepsis incapacitate the protein C pathway. One of the critical mediators of DIC is the release of a transmembrane glycoprotein tissue factor. This is released in response to exposure to cytokines or endotoxin and plays a major role in the development of DIC in septic conditions. For this reason, drotrecogin alfa is recommended in the therapy of DIC (8, 9). Additionally, a retrospective subgroup analysis of a clinical trial demonstrated a lower mortality rate among patients treated with drotrecogin alfa who met the criteria for DIC (10).

Hence, the conclusion is that in these spontaneous reports a manifestation of the underlying disease was reported as a possible adverse drug reaction. This hypothesis is further supported by the following.

- Clinical manifestation of DIC is extremely variable (9). The pathological processes involved deplete the body of its platelets and coagulation factors and

so, paradoxically, may lead to both thrombus formation and haemorrhage.

- Septic patients are generally treated in intensive care units but the adverse effect reporters (if disclosed) were mostly GPs, pharmacists and other health professionals, possibly not possessing detailed information.
- On consulting the WHO database, it can be seen that other reports on drotrecogin alfa between 2002 and 2007 specified various haemorrhages (the well-known adverse effects of drotrecogin alfa), as well as 43 reports of DIC itself.

Conclusion

In 13 reports of thrombosis associated with the use of drotrecogin alfa, retrieved from VigiBase, it appears likely that the reported thrombotic events represent a manifestation of the underlying disease process (severe sepsis), rather than an adverse reaction to any administered medicine. This analysis underlines the importance of considered assessment of all reported adverse drug reactions data.

References

1. Goshman L. Drotrecogin Alfa, Activated. *Journal of the Pharmacy Society of Wisconsin* Mar/Apr 2002;3335.
2. Sepsis.com – understanding sepsis and severe sepsis. www.sepsis.com/family_friends/understanding.jsp?reqNavId=5.2, downloaded 03.01.2008.
3. Cada DJ, Levien T. Drotrecogin Alfa. *Hospital Pharmacy* 2002;**37**(5):511–517.
4. Bernard GR, Vincent JI, Laterre PF. Efficacy and safety of recombinant human activated protein C for severe sepsis. *New England Journal of Medicine* 2001;**344**:699–709.
5. 1974–2207 Thomson MICROMEDEX Database.
6. Propofol. Merck Manual. www.merck.com/mmpe/lexicomp/propofol.htm, downloaded 08.08.2008.
7. GR Bernard et al. Extended evaluation of Recombinant Human Activated Protein C United States Trial (ENHANCE US). *Chest* 2004;**125**:2206–2216.
8. Becker JU, Wira CR. Disseminated Intravascular Coagulation. www.emedicine.com/emerg/topic150.htm, downloaded 07.08.2008.
9. Aysola A, Lopez-Plaza I. Disseminated Intravascular Coagulation. www.itxm.org/TMU1998/tmu3-99.htm, downloaded 07.08.2008.
10. Dhainaut JF et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without disseminated intravascular coagulation. *Journal of Thrombosis and Haemostasis* 2004;**2**(11):1924–1933.

Epidemiology and Prevention of Vaccine-Preventable Diseases



This book was produced by the Education, Information and Partnership Branch, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, who is solely responsible for its content. It was printed and distributed by the Public Health Foundation. For additional copies, contact the Public Health Foundation at 877-252-1200 or website <http://bookstore.phf.org/>.

Slide sets to accompany this book are available on the CDC Vaccines and Immunization website at <http://www.cdc.gov/vaccines/pubs/pinkbook/default.htm>.

E-mail address for comments, questions or suggestions about the contents of this book: nipinfo@cdc.gov.

EDITED BY:

William Atkinson, MD, MPH
Charles (Skip) Wolfe
Jennifer Hamborsky, MPH, CHES
Lynne McIntyre, MALS

CONTRIBUTIONS FROM:

PerStephanie Thompson, MS Ed
Donna Weaver, RN, MN
Steven Stewart

LAYOUT AND DESIGN:

Susie P. Childrey

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE CONTROL AND PREVENTION**

On the cover

"Die Spanische Krankheit" ("The Spanish Flu") ink drawing by Alfred Kubin, circa 1920. Kubin (1877-1959) studied in Munich and was associated with German expressionism. He was a contemporary of Edvard Munch, who also recorded his experience with the 1918 influenza pandemic. This work illustrates the figure of Death and the victims of the influenza pandemic in a way similar to that used in European woodcuts to depict the bubonic plague centuries earlier. The drawing is in a private collection.

Suggested Citation:

Centers for Disease Control and Prevention. *Epidemiology and Prevention of Vaccine-Preventable Diseases*. Atkinson W, Wolfe S, Hamborsky J, McIntyre L, eds. 11th ed. Washington DC: Public Health Foundation, 2009.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the Public Health Services or the U.S. Department of Health and Human Services. References to non-CDC sites on the Internet are provided as a service to readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses were current as of the date of publication.

Milestones in the History of Vaccination

400 BCE

Hippocrates describes diphtheria, epidemic jaundice, and other conditions

1100s

Variolation for smallpox first reported in China

1721

Variolation introduced into Great Britain

1796

Edward Jenner inoculates James Phipps with cowpox, and calls the procedure vaccination ("vacca" is Latin for cow)

Table of Contents

1 Principles of Vaccination	
Immunology and Vaccine-Preventable Diseases	1
Classification of Vaccines	4
Selected References	7
2 General Recommendations on Immunization	
Timing and Spacing of Vaccines	9
Adverse Reactions Following Vaccination	15
Contraindications and Precautions to Vaccination	16
Invalid Contraindications to Vaccination	23
Screening for Contraindications and Precautions to Vaccination	27
Selected References	30
3 Immunization Strategies for Healthcare Practices and Providers	
The Need for Strategies to Increase Immunization Levels	31
The AFIX Approach	33
Other Essential Strategies	38
Selected References	43
4 Vaccine Safety	
The Importance of Vaccine Safety Programs	45
Sound Immunization Recommendations and Policy	46
Methods of Monitoring Vaccine Safety	47
Vaccine Injury Compensation	52
The Immunization Provider's Role	52
Selected References	57
5 Diphtheria	
<i>Corynebacterium diphtheriae</i>	59
Pathogenesis	59
Clinical Features	59
Complications	61
Laboratory Diagnosis	61
Medical Management	62
Epidemiology	63
Secular Trends in the United States	64
Diphtheria Toxoid	65
Vaccination Schedule and Use	66
Contraindications and Precautions to Vaccination	67
Adverse Reactions Following Vaccination	67
Vaccine Storage and Handling	68
Suspect Case Investigation and Control	68
Selected References	69

Milestones in the History of Vaccination

1870

Louis Pasteur creates the first live attenuated bacterial vaccine (chicken cholera)

1884

Pasteur creates the first live attenuated viral vaccine (rabies)

1885

Pasteur first uses rabies vaccine in a human

1887

Institut Pasteur established

1900

Paul Ehrlich formulates receptor theory of immunity

Table of Contents

6 *Haemophilus influenzae*

<i>Haemophilus influenzae</i>	71
Pathogenesis	71
Clinical Features	73
Laboratory Diagnosis	73
Medical Management	74
Epidemiology	74
Secular Trends in the United States	75
<i>Haemophilus influenzae</i> type b Vaccines	76
Vaccination Schedule and Use	78
Combination Vaccines	80
Contraindications and Precautions to Vaccination	82
Adverse Reactions Following Vaccination	82
Vaccine Storage and Handling	82
Surveillance and Reporting of Hib Disease	83
Selected References	83

7 Hepatitis A

Hepatitis A Virus	85
Pathogenesis	85
Clinical Features	86
Complications	86
Laboratory Diagnosis	86
Medical Management	87
Epidemiology	87
Secular Trends in the United States	89
Case Definition	90
Hepatitis A Vaccine	90
Vaccination Schedule and Use	91
Contraindications and Precautions to Vaccination	95
Adverse Reactions Following Vaccination	96
Vaccine Storage and Handling	96
Postexposure Prophylaxis	96
Selected References	96

8 Hepatitis B

Hepatitis B Virus	99
Clinical Features	100
Complications	101
Laboratory Diagnosis	101
Medical Management	103
Epidemiology	103
Secular Trends in the United States	105
Hepatitis B Prevention Strategies	107

Milestones in the History of Vaccination

1901
First Nobel Prize in Medicine
to von Behring for
diphtheria antitoxin

1909
Theobald Smith discovers a method
for inactivating
diphtheria toxin

1919
Calmette and Guerin create BCG,
the first live attenuated
bacterial vaccine for humans

1923
First whole-cell pertussis vaccine tested
Gaston Ramon develops
diphtheria toxoid

1926
Ramon and Christian Zoeller
develop tetanus toxoid

Table of Contents

Hepatitis B Vaccine	107
Vaccination Schedule and Use	110
Serologic Testing of Vaccine Recipients	115
Postexposure Management	118
Contraindications and Precautions to Vaccination	121
Adverse Reactions Following Vaccination	121
Vaccine Storage and Handling	122
Selected References	122

9 Human Papillomavirus

Human Papillomavirus	123
Pathogenesis	123
Clinical Features	124
Laboratory Diagnosis	124
Medical Management	125
Epidemiology	125
Disease Burden in the United States	126
Prevention	127
Human Papillomavirus Vaccine	127
Vaccination Schedule and Use	129
Contraindications and Precautions to Vaccination	131
Adverse Reactions Following Vaccination	131
Vaccine Storage and Handling	132
Selected References	132

10 Influenza

Influenza Virus	135
Pathogenesis	137
Clinical Features	137
Complications	138
Impact of Influenza	138
Laboratory Diagnosis	139
Epidemiology	140
Secular Trends in the United States	140
Influenza Vaccine	141
Vaccination Schedule and Use	143
Contraindications and Precautions to Vaccination	147
Adverse Reactions Following Vaccination	148
Vaccine Storage and Handling	150
Year 2010 Objectives and Coverage Levels	151
Strategies for Improving Influenza Vaccine Coverage	151
Antiviral Agents for Influenza	152
Nosocomial Influenza Control	153
Influenza Surveillance	153
Selected References	154

Milestones in the History of Vaccination

1927
Yellow fever virus isolated

1931
Goodpasture describes a technique for viral culture in hens' eggs

1936
Thomas Francis and Thomas Magill develop the first inactivated influenza vaccine

1948
John Enders and colleagues isolate Lansing Type II poliovirus in human cell line

1954
Enders and Peebles isolate measles virus
Francis Field Trial of inactivated polio vaccine

Table of Contents

11 Measles

Measles Virus	157
Pathogenesis	157
Clinical Features	158
Complications	158
Laboratory Diagnosis	160
Epidemiology	161
Secular Trends in the United States	162
Classification of Measles Cases	165
Measles Vaccine	165
Vaccination Schedule and Use	167
Contraindications and Precautions to Vaccination	170
Adverse Reactions Following Vaccination	173
Vaccine Storage and Handling	174
Selected References	175

12 Meningococcal Disease

<i>Neisseria meningitidis</i>	177
Pathogenesis	178
Clinical Features	178
Laboratory Diagnosis	179
Medical Management	179
Epidemiology	180
Secular Trends in the United States	180
Meningococcal Vaccines	181
Vaccination Schedule And Use	183
Contraindications and Precautions to Vaccination	185
Adverse Reactions Following Vaccination	185
Vaccine Storage and Handling	186
Surveillance and Reporting of Meningococcal Disease	186
Antimicrobial Chemoprophylaxis	186
Selected References	187

13 Mumps

Mumps Virus	189
Pathogenesis	189
Clinical Features	189
Complications	190
Laboratory Diagnosis	191
Epidemiology	191
Secular Trends in the United States	192
Case Definition	192
Mumps Vaccine	193
Vaccination Schedule and Use	193

Milestones in the History of Vaccination

1955
Inactivated polio vaccine
licensed

1961
Human diploid cell line
developed

1963
Measles vaccine licensed
Trivalent oral polio vaccine licensed

1965
Bifurcated needle for
smallpox vaccine licensed

1966
World Health Assembly calls for
global smallpox eradication

Table of Contents

Contraindications and Precautions to Vaccination	195
Adverse Reactions Following Vaccination	196
Vaccine Storage and Handling	196
Selected References	197
14 Pertussis	
<i>Bordetella pertussis</i>	199
Pathogenesis	199
Clinical Features	199
Complications	200
Laboratory Diagnosis	201
Medical Management	202
Epidemiology	203
Secular Trends in the United States	203
Case Definition	205
Pertussis Vaccines	205
Vaccination Schedule and Use	207
Combination Vaccines Containing DTaP	210
Other DTaP Issues	212
Contraindications and Precautions to Vaccination	213
Adverse Reactions Following Vaccination	214
Vaccine Storage and Handling	216
Selected References	216
15 Pneumococcal Disease	
<i>Streptococcus pneumoniae</i>	217
Clinical Features	218
Laboratory Diagnosis	220
Medical Management	221
Epidemiology	221
Secular Trends in the United States	222
Pneumococcal Vaccines	222
Vaccination Schedule and Use	224
Contraindications and Precautions to Vaccination	227
Adverse Reactions Following Vaccination	228
Vaccine Storage and Handling	228
Goals and Coverage Levels	229
Selected References	229
16 Poliomyelitis	
Poliovirus	231
Pathogenesis	231
Clinical Features	232
Laboratory Diagnosis	233

Milestones in the History of Vaccination ➔

1967 Maurice Hilleman develops Jeryl Lynn strain of mumps virus	1969 Stanley Plotkin develops RA27/3 strain of rubella vaccine virus	1971 MMR vaccine licensed	1977 Last indigenous case of smallpox (Somalia)	1979 Last wild poliovirus transmission in the U.S.
--	---	-------------------------------------	--	---

Table of Contents

Epidemiology	233
Secular Trends in the United States	234
Poliovirus Vaccines	235
Vaccination Schedule and Use	237
Polio Vaccination of Adults	238
Contraindications And Precautions To Vaccination	239
Adverse Reactions Following Vaccination	240
Vaccine Storage and Handling	241
Outbreak Investigation and Control	241
Polio Eradication	242
Postpolio Syndrome	243
Selected References	243

17 Rotavirus

Rotavirus	245
Pathogenesis	245
Clinical Features	246
Complications	246
Laboratory Diagnosis	246
Epidemiology	247
Secular Trends in the United States	248
Rotavirus Vaccines	248
Vaccine Effectiveness	250
Duration of Immunity	250
Vaccination Schedule and Use	251
Contraindications and Precautions to Vaccination	252
Adverse Reactions Following Vaccination	254
Vaccine Storage and Handling	255
Rotavirus Surveillance	255
Selected References	256

18 Rubella

Rubella Virus	257
Pathogenesis	257
Clinical Features	257
Complications	258
Congenital Rubella Syndrome	258
Laboratory Diagnosis	259
Epidemiology	260
Secular Trends in the United States	261
Classification of Rubella Cases	262
Rubella Vaccine	263
Vaccination Schedule and Use	264

Milestones in the History of Vaccination

1981
First hepatitis B
vaccine licensed

1983
Smallpox vaccine withdrawn
from civilian market

1986
First recombinant vaccine
licensed (hepatitis B)
National Childhood Vaccine Injury Act

1989
Two-dose measles vaccine
recommendation

1990
First polysaccharide conjugate
vaccine licensed
(*Haemophilus influenzae* type b)

Table of Contents

Rubella Immunity	266
Contraindications and Precautions to Vaccination	267
Adverse Reactions Following Vaccination	268
Rubella Vaccination of Women of Childbearing Age	269
Vaccine Storage and Handling	270
Strategies to Decrease Rubella and CRS	270
Selected References	271

19 Tetanus

<i>Clostridium tetani</i>	273
Pathogenesis	274
Clinical Features	274
Complications	275
Laboratory Diagnosis	275
Medical Management	275
Wound Management	276
Epidemiology	276
Secular Trends in the United States	277
Tetanus Toxoid	278
Vaccination Schedule and Use	279
Contraindications and Precautions to Vaccination	280
Adverse Reactions Following Vaccination	281
Vaccine Storage and Handling	281
Selected References	282

20 Varicella

Varicella Zoster Virus	283
Pathogenesis	283
Clinical Features	283
Complications	285
Laboratory Diagnosis	286
Epidemiology	288
Secular Trends in the United States	289
Vaccines Containing Varicella Virus	290
Vaccination Schedule and Use	293
Varicella Immunity	296
Contraindications and Precautions to Vaccination	297
Zoster Vaccine	299
Adverse Reactions Following Vaccination	300
Transmission of Varicella Vaccine Virus	302
Vaccine Storage and Handling	302
Varicella Zoster Immune Globulin	303
Selected References	304

Milestones in the History of Vaccination

1994

Polio elimination certified
in the Americas
Vaccines for Children program begins

1995

Varicella vaccine licensed
Hepatitis A vaccine licensed
First harmonized childhood
immunization schedule published

1996

Acellular pertussis vaccine licensed
for infants

1997

Sequential polio vaccination
recommended

1998

First rotavirus
vaccine licensed

Table of Contents

APPENDICES

A Schedules and Recommendations

Immunization Schedules on the Web	A-1
Childhood Immunization Schedule 2009	A-2
Adult Immunization Schedule 2006–2009	A-5
Recommended Minimum Ages and Intervals	A-8
Summary of Recommendations for Childhood & Adolescent Immunizations	A-10
Summary of Recommendations for Adult Immunizations	A-13
Antibody—Live Vaccine Interval Table	A-16
Healthcare Worker Vaccination Recommendations	A-17
Immunization of Immunocompromised Patients Tables	A-18

B Vaccines

U.S. Vaccines	B-1
Selected Discontinued U.S. Vaccines	B-6
Vaccine Excipient and Media Summary, by Excipient	B-8
Vaccine Excipient and Media Summary, by Vaccine	B-15
Thimerosal Content in Some U.S. Licensed Vaccines	B-20
Pediatric/VFC Vaccine Price List	B-21
Adult Vaccine Price List	B-23
Influenza Vaccine Price List	B-23
Foreign Language Terms	B-24

C Vaccine Storage and Handling

Vaccine Storage & Handling Recommendations (2009)	C-1
Manufacturer Quality Control Phone Numbers	C-19
Checklist for Safe Vaccine Handling & Storage	C-20
Vaccine Handling Tips	C-21
Sample Refrigerator Warning Signs	C-22

D Vaccine Administration

"Vaccine Administration" Guidelines	D-1
Skills Checklist for Immunization	D-16
Immunization Site Maps	D-18
"Comforting Restraint" for Immunizations	D-23
Injectable Vaccine Administration: Birth–6 Years	D-24
Injectable Vaccine Administration: 7–18 Years	D-26
Medical Management of Vaccine Reactions (Children & Teens)	D-28
Medical Management of Vaccine Reactions (Adults)	D-30

1999 Exclusive use of inactivated polio vaccine recommended Rotavirus vaccine withdrawn	2000 Pneumococcal conjugate vaccine licensed for infants	2003 Live attenuated influenza vaccine licensed	2004 Inactivated influenza vaccine recommended for all children 6–23 months of age	2004 Indigenous transmission of rubella virus interrupted
--	--	---	--	---

Table of Contents

E Vaccine Information Statements

It's Federal Law	E-1
Instructions for Use of VISs	E-2
How to Get Vaccine Information Statements	E-3
VIS Questions and Answers	E-4
CDC's Vaccine Information Statement Webpage	E-8

F Vaccine Safety

The Vaccine Adverse Event Reporting System (VAERS)	F-1
Table of Reportable Events Following Vaccination	F-2
Vaccine Adverse Event Reporting System (VAERS) Form	F-4
The Vaccine Injury Compensation Program (VICP)	F-6
The VICP Vaccine Injury Table	F-7
Qualification and Aids to Interpretation of the Vaccine Injury Table	F-8

G Data and Statistics

Reported Cases and Deaths from Vaccine-Preventable Diseases: 1950–2008	G-1
Impact of Vaccines in the 20th & 21th Centuries	G-7
Vaccine Coverage Levels: 1962–2007	G-8

H Immunization Resources

National Immunization Contacts and Resources	H-1
IAC Online Directory of Immunization Resources	H-2
Sample IAC Print Materials	H-3
IAC <i>Express</i> Information Sheet	H-4
"Immunization Techniques" Video	H-5
Storage and Handling Toolkit	H-6
State and Local Immunization Grantee Contact Information	H-7

Milestones in the History of Vaccination ➔

2005 Acellular pertussis vaccines licensed for adolescents and adults	2005 MMR-varicella (MMRV) licensed	2006 Second generation rotavirus vaccine licensed	2006 First human papillomavirus vaccine licensed	2006 First herpes zoster vaccine licensed
---	--	--	---	--

Vaccines and Related Products Distributed in the United States

Vaccine/Biologic	Brand Name	Manufacturer	Type	How Supplied
Diphtheria, Tetanus, acellular Pertussis	Infranix®	GlaxoSmithKline	Inactivated	single-dose vial or syringe
Diphtheria, Tetanus, acellular Pertussis	Tripedia®	sanofi-pasteur	Inactivated	single-dose vial
Diphtheria, Tetanus, acellular Pertussis	Daptacel®	sanofi-pasteur	Inactivated	single-dose vial
Diphtheria, Tetanus, acellular Pertussis + Hib	TriHIBit®	sanofi-pasteur	Inactivated	single-dose vial
Diphtheria, Tetanus, acellular Pertussis +Hep B + IPV	Pediarix®	GlaxoSmithKline	Inactivated	single-dose vial or syringe
Diphtheria, Tetanus, acellular Pertussis + Hib + IPV	Pentacel®	sanofi-pasteur	Inactivated	single-dose vial
Diphtheria, Tetanus, acellular Pertussis + IPV	Kinrix®	GlaxoSmithKline	Inactivated	single-dose vial or syringe
Diphtheria, Tetanus (DT; ped <7yrs, P-free)	generic	sanofi-pasteur	Inactivated	single-dose vial
Tetanus, diphtheria, adsorbed (Td; >7yrs, P-free)	Decavac®	sanofi-pasteur	Inactivated	single-dose syringe
Tetanus, diphtheria, adsorbed (Td; >7yrs)	generic	Mass Biologic Labs	Inactivated	15-dose vial
Tetanus, diphtheria, acellular Pertussis (Tdap; 10-64 yrs)	Boostrix®	GlaxoSmithKline	Inactivated	single-dose vial or syringe
Tetanus, diphtheria, acellular Pertussis (Tdap; 11-64 yrs)	Adacel™	sanofi-pasteur	Inactivated	single-dose vial
Tetanus toxoid (TT; >7 yrs) adsorbed	generic	sanofi-pasteur	Inactivated	10-dose vial
Tetanus toxoid (TT; adult booster use only)	generic	sanofi-pasteur	Inactivated	15-dose vial
Tetanus immune globulin (TIG)	HyperTET™	Talecris	Human immunoglobulin	single-dose syringe
<i>Haemophilus influenzae</i> type b (PRP-T)	ActiHIB®	sanofi-pasteur	Inactivated	single-dose vial
<i>Haemophilus influenzae</i> type b (HbOC)	HibTITER®	Wyeth	Inactivated	single-dose vial
<i>Haemophilus influenzae</i> type b (PRP-OMP)	PedvaxHIB®	Merck	Inactivated	single-dose vial
<i>Haemophilus influenzae</i> type b (PRP-OMP) + Hep B	Comvax®	Merck	Inactivated	single-dose vial
Hepatitis A: ped/adol & adult formulations	Havrix®	GlaxoSmithKline	Inactivated	single-dose vial or syringe
Hepatitis A: ped/adol & adult formulations	Vaqta®	Merck	Inactivated	single-dose vial or syringe
Hepatitis A immune globulin	GamaSTAN™	Talecris	Human immunoglobulin	2 mL and 10 mL vials
Hepatitis B: ped/adol & adult formulations	Engerix-B®	GlaxoSmithKline	Inactivated	single-dose vial or syringe
Hepatitis B: ped/adol & adult formulations	Recombivax HB®	Merck	Inactivated	single-dose vial
Hepatitis B dialysis formulation	Recombivax HB®	Merck	Inactivated	single-dose vial
Hepatitis B immune globulin (HBIG)	HyperHEP B™	Talecris	Human immunoglobulin	1 mL syringe, 1 mL or 5 mL vial
Hepatitis B immune globulin (HBIG): ped formulation	HyperHEP B™	Talecris	Human immunoglobulin	single-dose 0.5 mL neonatal syringe
Hepatitis B immune globulin (HBIG)	Nabi-HB®	Nabi	Human immunoglobulin	single-dose vial
Hepatitis A & B: adult formulation	Twinrix®	GlaxoSmithKline	Inactivated	single-dose vial or syringe
Human papillomavirus (HPV)	Gardasil®	Merck	Inactivated	single-dose vial or syringe
Influenza (trivalent inactivated influenza vaccine [TIV])	Fluarix®	GlaxoSmithKline	Inactivated	10 single-dose syringes
Influenza (live attenuated influenza vaccine [LAIV])	FluMist®	Medimmune	Live, intranasal	10 single-use sprayers
Influenza (TIV)	Afluria®	CSL Biotherapies	Inactivated	single-dose syringe & 10-dose vial
Influenza (TIV)	Fluvirin®	Novartis	Inactivated	single-dose syringe & 10-dose vial
Influenza (TIV)	Fluzone®	sanofi-pasteur	Inactivated	10-dose vial
Influenza (TIV; >36 mos; no preservative)	Fluzone®	sanofi-pasteur	Inactivated	single-dose syringe (0.5 mL)
Influenza (TIV; ped 6-35 mos; no preservative)	Fluzone®	sanofi-pasteur	Inactivated	single-dose syringe (0.25 mL)
Influenza (TIV; >18 yrs)	FluLaval™	GlaxoSmithKline	Inactivated	10-dose vial
Measles, Mumps, Rubella (MMR)	M-M-R II®	Merck	Live, attenuated	single-dose vial
Measles, Mumps, Rubella + Varicella (MMRV)	ProQuad®	Merck	Live, attenuated	single-dose vial
Meningococcal conjugate (A/C/Y/W-135)	Menactra®	sanofi-pasteur	Inactivated	single-dose vial
Meningococcal polysaccharide (A/C/Y/W-135)	Menomune®	sanofi-pasteur	Inactivated	single-dose vial
Pneumococcal conjugate, 7-valent	Prevnar®	Wyeth	Inactivated	single-dose vial
Pneumococcal polysaccharide, 23-valent	Pneumovax 23®	Merck	Inactivated	single-dose vial or 5-dose vial
Polio (IPV)	IPOL®	sanofi-pasteur	Inactivated	single-dose syringe or 10-dose vial
Rotavirus	RotaTeq®	Merck	Live, oral	single-dose tube
Rotavirus	Rotarix®	GlaxoSmithKline	Live, oral	single-dose tube
Varicella	Varivax®	Merck	Live, attenuated	single-dose vial
Varicella Zoster Immune Globulin (VZIG) (IND)	VariZIG™	Cangene	Human Immunoglobulin	125-U vial
Zoster	Zostavax®	Merck	Live, attenuated	single-dose vial
Anthrax, adsorbed	BioThrax™	BioPort	Inactivated	multi-dose vial
Japanese encephalitis	JE-VAX®	sanofi-pasteur	Inactivated	single-dose vial
Rabies	Imovax®	sanofi-pasteur	Inactivated	single-dose vial
Rabies	RabAvert®	Novartis	Inactivated	single-dose vial
Rabies Immune Globulin (RIG)	Imogam Rabies-HT®	sanofi-pasteur	Human immunoglobulin	2 mL and 10 mL vials
Rabies Immune Globulin (RIG)	HyperRAB™	Talecris	Human immunoglobulin	2 mL and 10 mL vials
Typhoid VI polysaccharide	Typhim Vi®	sanofi-pasteur	Inactivated	single-dose syringe and 20-dose vial
Typhoid, live oral Ty21a	Vivotif®	Berna	Live, attenuated	4-capsule package
Yellow Fever	YF-Vax®	sanofi-pasteur	Live, attenuated	single- and 5-dose vial

Diphtheria

Diphtheria

Diphtheria is an acute, toxin-mediated disease caused by the bacterium *Corynebacterium diphtheriae*. The name of the disease is derived from the Greek *diphthera*, meaning leather hide. The disease was described in the 5th century BCE by Hippocrates, and epidemics were described in the 6th century AD by Aetius. The bacterium was first observed in diphtheritic membranes by Klebs in 1883 and cultivated by Löffler in 1884. Antitoxin was invented in the late 19th century, and toxoid was developed in the 1920s.

Corynebacterium diphtheriae

C. diphtheriae is an aerobic gram-positive bacillus. Toxin production (toxigenicity) occurs only when the bacillus is itself infected (lysogenized) by a specific virus (bacteriophage) carrying the genetic information for the toxin (tox gene). Only toxigenic strains can cause severe disease.

Culture of the organism requires selective media containing tellurite. If isolated, the organism must be distinguished in the laboratory from other *Corynebacterium* species that normally inhabit the nasopharynx and skin (e.g., diphtheroids).

C. diphtheriae has three biotypes—*gravis*, *intermedius*, and *mitis*. The most severe disease is associated with the *gravis* biotype, but any strain may produce toxin. All isolates of *C. diphtheriae* should be tested by the laboratory for toxigenicity.

Pathogenesis

Susceptible persons may acquire toxigenic diphtheria bacilli in the nasopharynx. The organism produces a toxin that inhibits cellular protein synthesis and is responsible for local tissue destruction and membrane formation. The toxin produced at the site of the membrane is absorbed into the bloodstream and then distributed to the tissues of the body. The toxin is responsible for the major complications of myocarditis and neuritis and can also cause low platelet counts (thrombocytopenia) and protein in the urine (proteinuria).

Clinical disease associated with non-toxin-producing strains is generally milder. While rare severe cases have been reported, these may actually have been caused by toxigenic strains that were not detected because of inadequate culture sampling.

Clinical Features

The incubation period of diphtheria is 2–5 days (range, 1–10 days).

Disease can involve almost any mucous membrane. For clinical purposes, it is convenient to classify diphtheria into a number of manifestations, depending on the site of disease.

Diphtheria

- Greek *diphthera* (leather hide)
- Recognized by Hippocrates in 5th century BCE
- Epidemics described in 6th century
- *C. diphtheriae* described by Klebs in 1883
- Toxoid developed in 1920s

Corynebacterium diphtheriae

- Aerobic gram-positive bacillus
- Toxin production occurs only when *C. diphtheriae* infected by virus (phage) carrying tox gene
- If isolated, must be distinguished from normal diphtheroid

Diphtheria Clinical Features

- Incubation period 2-5 days (range, 1-10 days)
- May involve any mucous membrane
- Classified based on site of infection
 - anterior nasal
 - pharyngeal and tonsillar
 - laryngeal
 - cutaneous
 - ocular
 - genital

Diphtheria

5

Pharyngeal and Tonsillar Diphtheria

- Insidious onset of exudative pharyngitis
- Exudate spreads within 2-3 days and may form adherent membrane
- Membrane may cause respiratory obstruction
- Fever usually not high but patient appears toxic

Anterior Nasal Diphtheria

The onset of anterior nasal diphtheria is indistinguishable from that of the common cold and is usually characterized by a mucopurulent nasal discharge (containing both mucus and pus) which may become blood-tinged. A white membrane usually forms on the nasal septum. The disease is usually fairly mild because of apparent poor systemic absorption of toxin in this location, and it can be terminated rapidly by antitoxin and antibiotic therapy.

Pharyngeal and Tonsillar Diphtheria

The most common sites of diphtheria infection are the pharynx and the tonsils. Infection at these sites is usually associated with substantial systemic absorption of toxin. The onset of pharyngitis is insidious. Early symptoms include malaise, sore throat, anorexia, and low-grade fever. Within 2–3 days, a bluish-white membrane forms and extends, varying in size from covering a small patch on the tonsils to covering most of the soft palate. Often by the time a physician is contacted, the membrane is greyish-green, or black if bleeding has occurred. There is a minimal amount of mucosal erythema surrounding the membrane. The membrane is adherent to the tissue, and forcible attempts to remove it cause bleeding. Extensive membrane formation may result in respiratory obstruction.

The patient may recover at this point; or if enough toxin is absorbed, develop severe prostration, striking pallor, rapid pulse, stupor, and coma, and may even die within 6 to 10 days. Fever is usually not high, even though the patient may appear quite toxic. Patients with severe disease may develop marked edema of the submandibular areas and the anterior neck along with lymphadenopathy, giving a characteristic “bullneck” appearance.

Laryngeal Diphtheria

Laryngeal diphtheria can be either an extension of the pharyngeal form or can only involve this site. Symptoms include fever, hoarseness, and a barking cough. The membrane can lead to airway obstruction, coma, and death.

Cutaneous (Skin) Diphtheria

In the United States, cutaneous diphtheria has been most often associated with homeless persons. Skin infections are quite common in the tropics and are probably responsible for the high levels of natural immunity found in these populations. Skin infections may be manifested by a scaling rash or by ulcers with clearly demarcated edges and membrane, but any chronic skin lesion may harbor *C. diphtheriae* along with other organisms. Generally, the organisms isolated

from recent cases in the United States were nontoxigenic. The severity of the skin disease with toxigenic strains appears to be less than in other forms of infection with toxigenic strains. Skin diseases associated with nontoxigenic strains are no longer reported to the National Notifiable Diseases Surveillance System in the United States.

Other sites of involvement include the mucous membranes of the conjunctiva and vulvovaginal area, as well as the external auditory canal.

Complications

Most complications of diphtheria, including death, are attributable to effects of the toxin. The severity of the disease and complications are generally related to the extent of local disease. The toxin, when absorbed, affects organs and tissues distant from the site of invasion. The most frequent complications of diphtheria are myocarditis and neuritis.

Myocarditis may present as abnormal cardiac rhythms and can occur early in the course of the illness or weeks later, and can lead to heart failure. If myocarditis occurs early, it is often fatal.

Neuritis most often affects motor nerves and usually resolves completely. Paralysis of the soft palate is most frequent during the third week of illness. Paralysis of eye muscles, limbs, and diaphragm can occur after the fifth week. Secondary pneumonia and respiratory failure may result from diaphragmatic paralysis.

Other complications include otitis media and respiratory insufficiency due to airway obstruction, especially in infants.

Death

The overall case-fatality rate for diphtheria is 5%–10%, with higher death rates (up to 20%) among persons younger than 5 and older than 40 years of age. The case-fatality rate for diphtheria has changed very little during the last 50 years.

Laboratory Diagnosis

Diagnosis of diphtheria is usually made on the basis of clinical presentation since it is imperative to begin presumptive therapy quickly.

Culture of the lesion is done to confirm the diagnosis. It is critical to take a swab of the pharyngeal area, especially any discolored areas, ulcerations, and tonsillar crypts. Culture medium containing tellurite is preferred because it provides a selective advantage for the growth of this organism.

Diphtheria Complications

- Most attributable to toxin
- Severity generally related to extent of local disease
- Most common complications are myocarditis and neuritis
- Death occurs in 5%-10%